Stevanato announced in their industrial plan for 2020 – 2023 that they intend to invest almost Euro 400 million in manufacturing and R&D programs for drug delivery systems. A share of this investment will be allocated to the manufacturing of ICOcap®. This update follows the announcement May 27 that ICOcap® received a CE-mark.
Stevanato also recently launched a new product site to increase the visibility of ICOcap® underlining its position as an important product for the future, where Iconovo is featured as a service provider for customizations and formulation services.
To find the press release for Stevanato’s industrial plan: https://www.stevanatogroup.com/news-events/press-releases/stevanato-group-planned-investments-under-the-2020-2023-industrial-plan-about-400-million-euros-to-finance-the-company-development/
To find Stevanato’s new ICOcap® site: https://www.stevanatogroup.com/drug-delivery-devices/icocap/
To read more about the CE-mark of ICOcap®: https://www.iconovo.se/capsule-inhaler-icocap-from-iconovo-ce-marked-for-clinical-trials/